Fundraising FoxAscenta Capital — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)Sean Harper Desmond Padhi(Founder)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)inDeborah Palestrant(Director)in
Co-investors5AM VenturesAccess BiotechnologyForesite CapitalKern Capital, LLCSanofi VenturesWestlake Village BioPartners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.